NurExone Biologic (OTCQB: NRXBF / TSXV: NRX): CEO Dr. Lior Shaltiel on How the Company Stands Out as an Early‑Clinical‑Stage Biotech

In this episode of WTR Healthcare Happenings, Dr. Lior Shaltiel, CEO of NurExone Biologic (OTCQB: NRXBF / TSXV: NRX), joins Tim Gerdeman and Robert Sassoon to discuss how the company is positioning itself as a standout early‑clinical‑stage biotech. Dr. Shaltiel breaks down NurExone’s focus on developing a first‑of‑its‑kind, non‑invasive therapy platform aimed at large markets with significant unmet needs, including spinal cord injury and other central nervous system conditions.The conversation explores how NurExone’s approach could open the door to new treatment possibilities, why the company believes its technology has the potential to reshape patient recovery, and what milestones investors should watch as the company advances through early clinical development. Dr. Shaltiel also shares insights into NurExone’s partnership strategy, regulatory path, and how the company is working to build long‑term value in a competitive biotech landscape.